Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.
1. STOCK NEWS:
- Southwest (LUV) expects to report a net loss in Q4 after holiday troubles [more]
- Baxter (BAX) will spin off Renal Care and Acute Therapies and plans to form a new operating model [more]
- WWE (WWE) said that Vince McMahon is returning to the board, which is undertaking a review of alternatives [more]
- McDonald's (MCD) will accelerate the pace of restaurant openings and evaluate staffing levels [more]
- The FDA granted accelerated approval for Biogen (BIIB) and Eisai's (ESALY) Alzheimer's drug [more]
2. WALL STREET CALLS:
- JPMorgan (JPM) and Bank of America (BAC) downgraded to Hold at Deutsche Bank [more]
- Lululemon (LULU) upgraded to Overweight from Equal Weight at Wells Fargo [more]
- Aligos (ALGS) was upgraded to Overweight at Piper and to Buy at Jefferies on derisking of NASH pill [more]
- Ulta Beauty (ULTA) downgraded to Underweight from Equal Weight at Wells Fargo [more]
- Silvergate Capital (SI) was downgraded to Hold at Craig-Hallum, cut to Neutral at JPMorgan and downgraded to Underperform at BofA with "more questions than answers" seen after its preliminary Q4 report [more]
3. AROUND THE WEB:
- Tesla (TSLA) cut Model 3 and Model Y prices in China after a delivery slump, WSJ reports more]
- Luminar (LAZR) shares are heading to under $1, Citron Research says [more]
- Bunzl (BZLFY) is seen as an "inflation winner," Barron's says [more]
- Raytheon (RTX) weighs the sale of its actuation unit, Bloomberg reports [more]
- Pfizer (PFE) in talks to license Chinese drugmakers for generic Paxlovid, Reuters says [more]
4. MOVERS:
- Aehr Test Systems (AEHR) increase after reporting quarterly results [more]
- Amarin (AMRN) higher after in New York after Jefferies upgraded the stock to Buy with a $3 price target [more]
- Fate Therapeutics (FATE) sinks after terminating its collaboration pact with Janssen (JNJ) [more]
- Atai Life (ATAI) declines after announcing its Phase 2a trial of PCN-101 did not meet its primary endpoint [more]
- XPeng (XPEV) lower after BofA downgraded the stock to Neutral with a $12.40 price target [more]
5. EARNINGS/GUIDANCE:
- Boot Barn (BOOT) reported mixed preliminary Q3 results [more]
- HTG Molecular (HTGM) reported upbeat preliminary 2022 revenue [more]
- Greenbrier (GBX) reported mixed Q1 results [more]
- Aurinia Pharmaceuticals (AUPH) reported upbeat preliminary Q4 revenue [more]
- Samsung (SSNLF) expects a year-over-year decline in Q4 operating profit [more]
INDEXES:
The Dow rose 700.53, or 2.13%, to 33,630.61, the Nasdaq gained 264.05, or 2.56%, to 10,569.29, and the S&P 500 advanced 86.98, or 2.28%, to 3,895.08.